Sun Hongbin's team of China Pharmaceutical University approved the clinical trial of class 1.1 new antithrombotic drug "Viagra tablet"

Sun Hongbin, a distinguished professor of "Yangtze River Scholar" from the Institute of Pharmaceutical Sciences, China Pharmaceutical University, and Jiangsu Weikeli pharmaceutical science and Technology Co., Ltd jointly developed a new chemical 1.1 antithrombotic drug, "vicagl tablets", which recently obtained the approval documents for phase I ~ III clinical trials of drugs issued by the State Food and drug administration Preclinical studies have shown that the active metabolites and mechanism of vecargrel are the same as that of clopidogrel, a widely used antithrombotic drug But the difference is that the key metabolic activation step of vicargyle is carried out in the gut, so it can avoid the CYP2C19 metabolic activation pathway of clopidogrel in the liver, and then it can prevent the drug resistance of CYP2C19 weak metabolism patients and the thrombotic cardiovascular events such as stent thrombosis In addition to being suitable for CYP2C19 patients with weak metabolism, Viagra is also suitable for CYP2C19 patients with normal metabolism, and it has the characteristics of quick onset, low dose and small side effects Some of the previous research results were published in the Journal of pharmaceutical chemistry, and were mainly reported in scibx, a journal of nature The project has been supported by the national science and technology major special project of "major new drug creation" during the 12th Five Year Plan period The institutions involved in preclinical research include Shanghai Institute of medicine, Chinese Academy of Sciences, Shanghai National Center for safety assessment of new drugs, Shandong University School of pharmacy, etc It is reported that the project team plans to officially launch the phase I clinical trial of wicagrel in June this year.